Business Context and Reporting Period
This Form 6-K filing by Takeda Pharmaceutical Company Limited, dated July 16, 2019, reports an extraordinary event regarding a change in specified subsidiaries. The filing is submitted pursuant to Japanese financial regulations and the U.S. Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses exclusively on corporate governance and subsidiary status changes.
Material Changes
The primary material change reported is the decision to liquidate Shire Limited (formerly Shire plc), a specified subsidiary of Takeda.
- Subsidiary Details: Shire Limited, headquartered in Dublin, Republic of Ireland, with a capital of GBP 46,275,411.
- Ownership Change: Takeda's voting rights in Shire Limited have changed from 100.0% (925,508,211 votes) prior to liquidation to 0.0% (0 votes) following the decision.
- Timeline: Administrative processes for liquidation will commence in due course; the completion date is currently undetermined.
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, future outlook, or specific risk factors beyond the procedural note that liquidation completion dates are subject to local regulations. The document serves as a formal notification of the resolution to liquidate the subsidiary.
Investor Verification Checklist
- Verify the regulatory status and timeline for the liquidation of Shire Limited in Ireland.
- Confirm the impact of this liquidation on Takeda's consolidated financial statements and goodwill impairment testing.
- Review subsequent filings for the final completion date of the liquidation process.
- Check for any related restructuring costs or one-time charges associated with the dissolution of Shire Limited.